Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients (CHART)
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Sponsor: Mallinckrodt
Listed as NCT01386554, this PHASE4 trial focuses on Idiopathic Membranous Nephropathy and Proteinuria and remains completed. Sponsored by Mallinckrodt, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Jun 2017 — Apr 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
For direct contact, visit the study record on ClinicalTrials.gov .